Enhancing monoclonal antibodies with natural products: Mechanisms and applications

Abstract

Monoclonal antibodies (mAbs) have revolutionized therapeutic strategies across a broad spectrum of diseases, yet their efficacy remains constrained by challenges such as suboptimal tumor penetration and insufficient cytotoxicity. This study pioneers an integrative approach, harnessing the untapped potential of plant-derived glycosides and innovative biotechnological advances to redefine mAb efficacy. Specifically, we investigate the novel application of beta-glucan analogs engineered for enhanced immunomodulatory effects, targeting not only malignant cells but also the tumor microenvironment to optimize mAb penetration. Moreover, we introduce a groundbreaking strategy in antibody-drug conjugates (ADCs) by leveraging previously unexploited natural toxins, such as modified saporin variants, which are bioengineered to achieve selective cytotoxicity with minimal offtarget effects. This novel ADC formulation is further optimized through the use of nanoencapsulation techniques, ensuring precise delivery and controlled release within the tumor milieu. The research also focuses on hybrid expression systems, scalable mAb production, nanoencapsulation for targeted delivery, and the integration of natural and synthetic techniques for improved antibody therapies. By combining plant-based expression systems with synthetic biology tools, creating a hybrid platform that surpasses traditional plant or mammalian systems in both yield and safety. This approach not only reduces production costs but also introduces a scalable method for the rapid adaptation of mAbs in response to emerging pathogens or tumor mutations. This study opens new avenues by blending natural and synthetic methodologies, ultimately enhancing the therapeutic outcomes of mAbs across various disease states. It underscores the transformative potential of integrating cutting-edge technologies with natural compounds, paving the way for more effective, targeted, and adaptable antibody-based therapies.

Keywords

Monoclonal antibody / Natural product / Adjuvant / Transgenic plant system

References

[1] Kaur Harleen . Chapter 1-overview of monoclonal antibodies. In: Kaur Harleen, Reusch Dietmar, eds. Monoclonal Antibodies. Academic Press; 2021; 1- 29. ISBN 9780128223185.

[2] Duan L , Mukherjee E . Janeway's immunobiology. In: Yale J Biol Med. 9th ed. PMCID; 2016 Sep 30: 424- 425. PMC5045153;89(3).

[3] Köhler G , Milstein C . Continuous cultures of fused cells secreting antibody of predefined specificity. Nature. 1975 Aug 7; 256 (5517): 495- 497. PMID: 1172191.

[4] Singh Surjit , Tank Nitish K , Dwiwedi Pradeep , et al. Monoclonal antibodies: a review. Curr Clin Pharmacol. May 1, 2018; 13 (2): 85- 99.

[5] Cazzola Mario , Ora Josuel , Cavalli Francesco , Rogliani Paola , Matera Maria Gabriella . An overview of the safety and efficacy of monoclonal antibodies for the chronic obstructive pulmonary disease. Biol Targets & Ther. 2021; 15 (August 27): 363- 374.

[6] Thakkar S , Chopra A , Nagendra L , Kalra S , Bhattacharya S . Teplizumab in type 1 diabetes mellitus: an updated review. touchREV Endocrinol. 2023 Nov; 19 (2): 22- 30. Epub 2023 Oct 6. PMID: 38187075; PMCID: PMC10769466.

[7] Ellis CR , Azmat CE , Adalimumab . In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2024 Jan [Updated 2023 Nov 12]

[8] Doevendans Erik , Schellekens Huub . Immunogenicity of innovative and biosimilar monoclonal antibodies. Antibodies. 2019;8(1):21. “Antibodies | Free Full-Text | Monoclonal Antibodies in Cancer Therapy Accessed May 10, 2024.

[9] Rawat Sushama , Hussain Md Sadique , Mohapatra Chandan , Kaur Gurleen . An overview of monoclonal antibodies and their therapeutic applications. Journal NVEO. 2021; 4121- 4130.

[10] Deb Paroma , Maruf Ahmed Molla Md , Saif-Ur-Rahman KM . An update to monoclonal antibody as therapeutic option against COVID-19. Biosafety Health. April 2021; 3 (2): 87- 91.

[11] Rodriguez-Fernandez Rosa , Mejias Asuncion , Ramilo Octavio . Monoclonal antibodies for prevention of respiratory syncytial virus infection. Pediatr Infect Dis J. May 2021; 40 (5S): S35.

[12] Kardol-Hoefnagel , Tineke BSc1 , Otten Henny G PhD1 . A comprehensive overview of the clinical relevance and treatment options for antibody-mediated rejection associated with non-HLA antibodies. Transplantation. July 2021; 105 (7): 1459- 1470.

[13] Barbier L , Ebbers HC , Declerck P , Simoens S , Vulto AG , Huys I . The efficacy, safety, and immunogenicity of switching between reference biopharmaceuticals and biosimilars: a systematic review. Clin Pharmacol Ther. 2020; 108: 734- 755.

[14] Kesik-Brodacka M . Progress in biopharmaceutical development. Biotechnol Appl Biochem. 2018; 65: 306- 322.

[15] Stryjewska Agnieszka , Kiepura Katarzyna , Librowski Tadeusz , Lochyński Stanisław . Biotechnology and genetic engineering in the new drug development. Part II. Monoclonal antibodies, modern vaccines and gene therapy. Pharmacol Rep. September 1, 2013; 65 (5): 1086- 1101.

[16] Pedrioli Alessandro , Oxenius Annette . Single B cell technologies for monoclonal antibody discovery. Trends Immunol. December 1, 2021; 42 (12): 1143- 1158.

[17] Lipman Neil S , Jackson Lynn R , Trudel Laura J , Weis-Garcia Frances . Monoclonal versus polyclonal antibodies: distinguishing characteristics, applications, and information resources. ILAR J. 2005; 46 (3): 258- 268.

[18] Kumar Rajesh , Kumari Ruchi , Khan Lubina , et al. Isolation and characterization of cross-neutralizing human anti-V3 single-chain variable fragments (scFvs) against HIV-1 from an antigen preselected phage library. Appl Biochem Biotechnol. 2019; 187: 1011- 1027.

[19] Zaroff Samantha , Tan Grace . Hybridoma technology: the preferred method for monoclonal antibody generation for in vivo applications. Biotechniques. 2019; 67 (3): 90- 92.

[20] Zhang Chonghui . Hybridoma technology for the generation of monoclonal antibodies. Antibody methods and protocols. 2012; 117- 135.

[21] Hilal Ahmed Parray , Shukla Shivangi , Samal Sweety , et al. Hybridoma technology a versatile method for isolation of monoclonal antibodies, its applicability across species, limitations, advancement and future perspectives. Int Immunopharm. 2020; 85: 106639. ISSN 1567-5769.

[22] Mitra Sanchita , Chaudhary Tomar Pushpa . Hybridoma technology; advancements, clinical significance, and future aspects. J Genet Eng Biotechnol. 2021; 19: 1- 12.

[23] Shi W , Liao Y , Willis SN , et al. Transcriptional profiling of mouse B cell terminal differentiation defines a signature for antibody-secreting plasma cells. Nat Immunol. 2015; 16 (6): 663- 673.

[24] Ganguly Subha , Wakchaure Rajesh . Hybridoma technology: a brief review on its diagnostic and clinical significance. Pharmaceut Biol Eval. 2016; 3 (6): 554- 555.

[25] Sauter ER . Cancer prevention and treatment using combination therapy with natural compounds. Expet Rev Clin Pharmacol. 2020 Mar; 13 (3): 265- 285. Epub 2020 Apr 3. PMID: 32154753.

[26] Strasser R . Plant protein glycosylation. Glycobiology. 2016 Sep; 26 (9): 926- 939. Epub 2016 Feb 23. PMID: 26911286; PMCID: PMC5045529.

[27] Komarova Tatiana V , Sheshukova Ekaterina V , Dorokhov Yuri L . Plant-made antibodies: properties and therapeutic applications. Curr Med Chem. January 1, 2019; 26 (3): 381- 395.

[28] Ko K , Koprowski H . Plant biopharming of monoclonal antibodies. Virus Res. 2005 Jul; 111 (1): 93- 100. Epub 2005 Apr 19. PMID: 15896408.

[29] Yano A , Maeda F , Takekoshi M . Transgenic tobacco cells producing the human monoclonal antibody to hepatitis B virus surface antigen. J Med Virol. 2004 Jun; 73 (2): 208- 215. PMID: 15122794.

[30] Zeitlin L , Olmsted SS , Moench TR , et al. A humanized monoclonal antibody produced in transgenic plants for immunoprotection of the vagina against genital herpes. Nat Biotechnol. 1998 Dec; 16 (13): 1361- 1364. PMID: 9853620.

[31] Sangprasat K , Bulaon CJI , Rattanapisit K , et al. Production of monoclonal antibodies against botulinum neurotoxin in Nicotiana benthamiana. Hum Vaccines Immunother. 2024: 20 (1).

[32] Fischer R , Schillberg S , Twyman RM . Molecular farming of antibodies in plants. In: Recent Advances in Plant Biotechnology. Boston, MA: Springer; 2009.

[33] Nessa Meher Un , Rahman Md Atiar , Kabir Yearul . Plant-produced monoclonal antibody as immunotherapy for cancer. BioMed Res Int. August 25, 2020; 2020: e3038564.

[34] Chen Q . Development of plant-made monoclonal antibodies against viral infections. Curr Opin Virol. 2002;51:521–531. https://doi.org/10.1007/s00262-002-0309-z, 2022 Feb;52:148-160. doi: 10.1016/j.coviro.2021.12.005. Epub 2021 Dec 18. PMID: 34933212; PMCID: PMC8844144.K. Dredge, Blake Marriott, S. Todryk and A. Dalgleish. "Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy." Cancer Immunology, Immunotherapy.

[35] Ponte Jose F , Ponath P , Gulati R , et al. Enhancement of humoral and cellular immunity with an anti-glucocorticoid-induced tumour necrosis factor receptor monoclonal antibody. Immunology. 2010; 130.

[36] Bonam S , Partidos C , Halmuthur Sampath Kumar M , Muller S . An overview of novel adjuvants designed for improving vaccine efficacy. Trends Pharmacol Sci. 2017; 38 9: 771- 793.

[37] Khayyati Kohnehshahri Mahsa , Delirezh N , Maleki Leili Aghebati . CpG-containing oligodeoxynucleotides and freund adjuvant in combination with alum augment the production of monoclonal antibodies against recombinant HBsAg. Avicenna J Med Biotechnol (AJMB). 2022; 14: 125- 131.

[38] Tiong G , Gill H , Lofthouse S , Puri N . Comparison of conventional adjuvants and ‘adjuvant-free' monoclonal antibody targeting for stimulating antibody responses against a conjugate of luteinizing hormone releasing hormone and avidin. Vaccine. 1993; 11 4: 425- 430.

[39] Dredge K , Blake Marriott , Todryk S , Dalgleish A . Adjuvants and the promotion of Th1-type cytokines in tumour immunotherapy. Cancer Immunol Immunother. 2002; 51: 521- 531.

[40] Gerber Hans-Peter , Koehn Frank E , Abraham Robert T . The antibody-drug conjugate: an enabling modality for natural product-based cancer therapeutics. Nat Prod Rep. May 2013; 30 (5): 625- 639.

[41] FitzGerald D , Wayne A , Kreitman R , Pastan I . Treatment of hematologic malignancies with immunotoxins and antibody-drug conjugates. Cancer Res. 2011; 71 20: 6300- 6309.

[42] Wen-Qian Li , Guo Han-Fei , Li Lingyu , Zhang Yong-fei , Cui J . The promising role of antibody drug conjugate in cancer therapy: combining targeting ability with cytotoxicity effectively. Cancer Med. 2021; 10: 4677- 4696.

[43] Matthew R Trendowski . Recent advances in the development of antineoplastic agents derived from natural products. Drugs. 2015; 75: 1993- 2016.

[44] Gilabert-Oriol R , Thakur M , Mallinckrodt BV , et al. Abstract A83: combinatorial approach to drastically enhance the monoclonal antibody efficacy in targeted tumor therapy. Mol Cancer Therapeut. 2013; 12.

[45] Singh H , Gullaiya S , Kaur Ishpreet . Antibody drug conjugates: a leap ahead in cancer treatment. J Drug Deliv Therapeut. 2014; 4: 52- 59.

[46] Gilabert-Oriol R , Thakur M , Mallinckrodt BV , et al. Abstract A83: combinatorial approach to drastically enhance the monoclonal antibody efficacy in targeted tumor therapy. Mol Cancer Therapeut. 2013; 12.

[47] Hong F , Hansen Richard D , Yan Jun , et al. Beta-glucan functions as an adjuvant for monoclonal antibody immunotherapy by recruiting tumoricidal granulocytes as killer cells. Cancer Res. 2003; 63 24: 9023- 9031.

[48] Trail Pamela A , Bianchi Albert B . Monoclonal antibody drug conjugates in the treatment of cancer. Curr Opin Immunol. 1999; 11 (5): 584- 588.

[49] Wels W , Biburger M , Müller T , et al. Recombinant immunotoxins and retargeted killer cells: employing engineered antibody fragments for tumor-specific targeting of cytotoxic effectors. Cancer Immunol Immunother. 2004; 53: 217- 226.

[50] Weiner L , Dhodapkar M , Ferrone S . Monoclonal antibodies for cancer immunotherapy. Lancet. 2009; 373: 1033- 1040.

[51] Verma SK , Mahajan P , Singh NK , et al. New-age vaccine adjuvants, their development, and future perspective. Front Immunol. 2023 Feb 24; 14: 1043109. PMID: 36911719; PMCID: PMC9998920.

[52] Dey AK , Srivastava IK . Novel adjuvants and delivery systems for enhancing immune responses induced by immunogens. Expert review of vaccines. 2011; 10 (2): 227- 251.

RIGHTS & PERMISSIONS

The Authors. Publishing services by Elsevier B.V. on behalf of Higher Education Press and KeAi Communications Co. Ltd.